A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
- 18 September 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 141 (4), 761-769.e2
- https://doi.org/10.1016/j.jid.2020.06.039
Abstract
No abstract availableKeywords
Funding Information
- Assistance Publique - Hôpitaux de Paris
This publication has 36 references indexed in Scilit:
- Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusionsLaboratory Investigation, 2018
- Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear‐cell renal cell carcinoma patients treated with sunitinibBJU International, 2016
- CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma ProtuberansMolecular Cancer Therapeutics, 2015
- Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium ReportJournal of Clinical Oncology, 2013
- No Correlation between the Molecular Subtype of COL1A1–PDGFB Fusion Gene and the Clinico-Histopathological Features of Dermatofibrosarcoma ProtuberansJournal of Investigative Dermatology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Dermatofibrosarcoma Protuberans Treated at a Single Institution: A Surgical Disease With a High Cure RateJournal of Clinical Oncology, 2005
- Gene Expression Profiling of Human Sarcomas: Insights into Sarcoma BiologyCancer Research, 2005
- Vascular Endothelial Growth Factor and Soft Tissue Sarcomas: Tumor Expression Correlates With GradeAnnals of Surgical Oncology, 2001
- Sample size tables for exact single‐stage phase II designsStatistics in Medicine, 2001